AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEXT SCIENCE LTD

0.137

+0.0021.48%

Volume:1.57K

Turnover:219.00

Market Cap:40.09M

PE:-2.82

High:0.140

Open:0.140

Low:0.137

Close:0.135

52wk High:0.155

52wk Low:0.056

Shares:292.63M

Float Shares:139.47M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.049

EPS(LYR):-0.054

ROE:-289.70%

ROA:-50.99%

PB:-47.91

PE(LYR):-2.51

Loading ...

Overview Company News Filings

BRIEF-Next Science Releases Quarterly Activity Report

Next Science Ltd - 2Q FY25 Product Sales of US$5.2M

THOMSON REUTERS

Appendix 3Y - I.V. Hall-NXS.AX

Cleansing notice-NXS.AX

Application for quotation of securities - NXS-NXS.AX

BUZZ-Australia's Next Science surges on sale of assets for $50 million

ASX ALERT-Next Science to Sell Majority of Assets-NXS.AX

Next Science Says Complaint Filed by Ex-Employee Dismissed by Court; Shares Up 4%

MT Newswires Live

BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court

BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3M

BRIEF-Next Science Posts Loss For The Year Of $10.6 Mln

Next Science Receives FDA Warning Letter Over Marketing Claims, Quality Issues; Shares Fall 8%

MT Newswires Live

BRIEF-Next Science Receives FDA Warning Letter

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NXS.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NXS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NXS.AU\",,,,,undefined,":{"symbol":"NXS.AU","market":"AU","secType":"STK","nameCN":"NEXT SCIENCE LTD","latestPrice":0.137,"timestamp":1765516320000,"preClose":0.135,"halted":0,"volume":1571,"delay":0,"nameEN":"NEXT SCIENCE LTD","floatShares":139470662,"shares":292625365,"eps":-0.04852335887036202,"marketStatus":"Not Yet Opened","change":0.002,"latestTime":"12-12 16:12:00 AEDT","open":0.14,"high":0.14,"low":0.137,"amount":219,"amplitude":0.022222,"askPrice":0.14,"askSize":213439,"bidPrice":0.135,"bidSize":442653,"shortable":3,"etf":0,"ttmEps":-0.04852335887036202,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765753200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.135,"openAndCloseTimeList":[[1765494000000,1765515600000]],"volumeRatio":0.0030940216257020845,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NXS.AU\",,,,,undefined,":{"symbol":"NXS.AU","floatShares":139470662,"roa":"-50.99%","roe":"-289.70%","lyrEps":-0.054478,"volumeRatio":0.0030940216257020845,"shares":292625365,"dividePrice":0,"high":0.14,"amplitude":0.022222,"preClose":0.135,"low":0.137,"week52Low":0.056,"pbRate":"-47.91","psRate":"1.21","week52High":0.155,"institutionHeld":0,"latestPrice":0.137,"committee":0.349363,"eps":-0.04852335887036202,"divideRate":0,"volume":1571,"delay":0,"ttmEps":-0.04852335887036202,"open":0.14,"prevYearClose":0.115,"prevWeekClose":0.14,"prevMonthClose":0.145,"prevQuarterClose":0.15,"fiveDayClose":0.14,"twentyDayClose":0.145,"sixtyDayClose":0.147},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXS.AU\",params:#limit:5,,,undefined,":[{"date":"2025-04-24","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745452800000,"name":null,"time":"","dateTimestamp":1745416800000,"actualEps":null},{"date":"2025-02-27","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740610800000,"name":null,"time":"","dateTimestamp":1740574800000,"actualEps":null},{"date":"2025-01-22","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1737500400000,"name":null,"time":"","dateTimestamp":1737464400000,"actualEps":null},{"date":"2024-10-21","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1729465200000,"name":null,"time":"","dateTimestamp":1729429200000,"actualEps":null},{"date":"2024-08-30","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724976000000,"name":null,"time":"","dateTimestamp":1724940000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXS.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXS.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555761110","title":"BRIEF-Next Science Releases Quarterly Activity Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2555761110","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555761110?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:30","pubTimestamp":1753925443,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Releases Quarterly Activity Report July 31 (Reuters) - Next Science Ltd NXS.AX:QUARTERLY ACTIVITY REPORT & APPENDIX 4C - 30 JUNE2Q FY25 PRODUCT SALES OF US$5.2M2Q FY25 DIRECT PRODUCT SALES OF US$3.3MFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUE6K7RQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2555020772","title":"Next Science Ltd -  2Q FY25 Product Sales of US$5.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2555020772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555020772?lang=en_us&edition=fundamental","pubTime":"2025-07-31 06:38","pubTimestamp":1753915089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUE6K7RQ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2551972195","title":"Appendix 3Y - I.V. Hall-NXS.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551972195","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551972195?lang=en_us&edition=fundamental","pubTime":"2025-07-14 14:35","pubTimestamp":1752474906,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nASXPZ5pb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nASX2628K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2551721189","title":"Cleansing notice-NXS.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551721189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551721189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 14:34","pubTimestamp":1752474856,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nASX1x8Dcx","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nASX15drK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2550728186","title":"Application for quotation of securities - NXS-NXS.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550728186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550728186?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:21","pubTimestamp":1752189697,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASX8jl1VH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX8TKLMy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2548044287","title":"BUZZ-Australia's Next Science surges on sale of assets for $50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2548044287","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548044287?lang=en_us&edition=fundamental","pubTime":"2025-07-01 09:04","pubTimestamp":1751331868,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Next Science surges on sale of assets for $50 million** Next Science shares NXS.AX surge 70.1% to A$0.12, after earlier jumping as much as 123.9% for record pct gain** Medical tech firm to sell majority assets to Demetra Holdings for $50 mln** Co estimates net proceeds from deal to be around $30 mln** Trading volume at about 1.5 mln shares, 6.8x 30-day average** Stock down 41.7% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL4N3SY028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2548045785","title":"ASX ALERT-Next Science to Sell Majority of Assets-NXS.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548045785","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548045785?lang=en_us&edition=fundamental","pubTime":"2025-07-01 06:28","pubTimestamp":1751322510,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX64FKft","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX22654m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2533373229","title":"Next Science Says Complaint Filed by Ex-Employee Dismissed by Court; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533373229","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533373229?lang=en_us&edition=fundamental","pubTime":"2025-05-05 11:23","pubTimestamp":1746415391,"startTime":"0","endTime":"0","summary":"Next Science  said the derivative complaint filed by former employee Michael Morello in Florida's Duval County Court has been dismissed for lack of standing, according to a Monday filing with the Australian bourse.The complaint alleges that the company's Xbio technology has not been approved by the US Food and Drug Administration for biofilm eradication and that the company failed to address safety concerns regarding its Xperience surgical solution in breast implant procedures, the company said in a Jan. 8 filing.The litigation initiated by the company against Morello and other former employees for breach of post-employment restraints is underway.Next Science's shares rose more than 4% in midday trade Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2533322606","title":"BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2533322606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533322606?lang=en_us&edition=fundamental","pubTime":"2025-05-05 09:05","pubTimestamp":1746407130,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court May 5 (Reuters) - Next Science Ltd NXS.AX:DERIVATIVE COMPLAINT FILED BY INDIVIDUAL BEEN DISMISSED BY COURT FOR LACK OF STANDINGFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RA2AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2529696884","title":"BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2529696884","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529696884?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:03","pubTimestamp":1745453026,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3MApril 24 (Reuters) - Next Science NXS.AX:1Q FY25 PRODUCT SALES OF US$5.3MFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R11AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU"],"gpt_icon":0},{"id":"2514656363","title":"BRIEF-Next Science Posts Loss For The Year Of $10.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514656363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514656363?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:06","pubTimestamp":1740704776,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Posts Loss For The Year Of $10.6 MlnFeb 28 (Reuters) - Next Science Ltd NXS.AX:LOSS FOR THE YEAR $10.6 MILLIONFY REVENUES FROM ORDINARY ACTIVITIES UP 3% TO $ 22.8 MILLIONFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI1UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514433058","title":"Next Science Receives FDA Warning Letter Over Marketing Claims, Quality Issues; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514433058","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514433058?lang=en_us&edition=fundamental","pubTime":"2025-02-25 14:54","pubTimestamp":1740466497,"startTime":"0","endTime":"0","summary":"Next Science  has received a warning letter from the US Food and Drug Administration  following an inspection of its Jacksonville, Florida facility in August and September 2024, according to a Tuesday filing with the Australian bourse.In its letter, the FDA determined that the company's Xperience, Blastx, and Surgx products did not have premarket approval related to certain marketing and labeling claims, the filing said.The FDA also identified potential quality system violations during the inspection of the facility.The company has implemented corrective actions and is working with the FDA to resolve the matters, while a follow-up inspection will be required to assess progress, the filing added.Shares of the company fell past 8% at market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514703089","title":"BRIEF-Next Science Receives FDA Warning Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514703089","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514703089?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:29","pubTimestamp":1740446987,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Receives FDA Warning LetterFeb 25  - Next Science Ltd NXS.AX:NEXT SCIENCE RECEIVES FDA WARNING LETTERWARNING LETTER RELATES TO FDA'S INSPECTION OF CO'S JACKSONVILLE, FLORIDA FACILITY DURING AUG & SEPT 2024UNDERTAKEN CORRECTIVE ACTIONS TO ADDRESS MATTERS RAISED BY FDA, INCLUDING REVISING PRODUCT DESCRIPTIONS ON CO'S WEBSITEFurther company coverage: NXS.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}